Show simple item record

dc.contributor.authorSwanepoel, Albe C.
dc.contributor.authorDe Lange, Zelda
dc.contributor.authorVisagie, Amcois
dc.contributor.authorEmmerson, Odette
dc.contributor.authorNielsen, Vance G.
dc.contributor.authorPretorius, Etheresia
dc.date.accessioned2017-05-15T07:22:13Z
dc.date.available2017-05-15T07:22:13Z
dc.date.issued2016
dc.identifier.citationSwanepoel, A.C. et al. 2016. The clinical relevance of altered fibrinogen packaging in the presence of 17β-estradiol and progesterone. Thrombosis research, 146:23-34. [http://dx.doi.org/10.1016/j.thromres.2016.08.022]
dc.identifier.issn0049–3848
dc.identifier.issn1879-2472 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/23120
dc.identifier.urihttp://dx.doi.org/10.1016/j.thromres.2016.08.022
dc.description.abstractBackground The effect of endogenous hormone concentrations, specifically 17β-estradiol and progesterone, on fibrin network formation has not been established. Objectives It is essential to understand natural hormone mechanisms since these hormones are still present in circulation while hormonal contraceptives, which are associated with increased risk of venous thromboembolism, are used. Methods Due to the fact that these hormones are known to increase hypercoagulability and the prothrombotic state scanning electron microscopy (SEM), atomic force microscopy (AFM), thromboelastography (TEG) and turbidimetry were employed to investigate the morphology, surface roughness, viscoelastic properties and formation and lysis of fibrin. Results 17β-estradiol and progesterone showed hypercoagulable viscoelastic properties and decreased the diameter and surface roughness of fibrin while increasing dense matted deposit occurrence. Our results suggest that the additional burden of hormonal load, together with the presence of endogenous estrogen and progesterone, may result in a prothrombotic and hypercoagulable state in females with an inflammatory predisposition. Conclusion Our results are of clinical importance when considering hormones as either pathological agent or therapeutic intervention as will be assessed in future investigation
dc.language.isoen
dc.publisherElsevier
dc.subject17β-Estradiol
dc.subjectFibrinogen
dc.subjectFibrin
dc.subjectProgesterone
dc.subjectThrombophilia
dc.titleThe clinical relevance of altered fibrinogen packaging in the presence of 17β-estradiol and progesterone
dc.typeArticle
dc.contributor.researchID20124805 - De Lange, Zelda


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record